Cargando…
Long-term drug costs per life-month gained associated with first-line treatments for unresectable or metastatic melanoma
BACKGROUND: For unresectable or metastatic melanoma, first-line ipilimumab has demonstrated long-term survival benefits over a 7-year period. First-line treatment with BRAF inhibitors has demonstrated efficacy in clinical trials with up to 3 years of follow-up. The long-term comparative efficacy and...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2016
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4827222/ https://www.ncbi.nlm.nih.gov/pubmed/27069772 http://dx.doi.org/10.1186/s40164-016-0039-0 |